Myelodysplastic Syndromes (MDS)

Ryotaro Nakamura, MD

Institution

City of Hope

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Chronic Lymphocytic Leukemia (CLL)

Chronic Myelomonocytic Leukaemia (CMML)

Graft Versus Host Disease (GVHD)

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Pure Red Cell Aplasia (PRCA)

About

Ryotaro Nakamura, MD is Professor, Department of Hematology & Hematopoietic Cell Transplantation; Director, Center for Stem Cell Transplantation at City of Hope. Since joining City of Hope in 2002, Ryotaro Nakamura, M.D., has been at the forefront of leading-edge research in stem cell transplantation and development of cancer vaccines. Among his promising projects: A study indicating that bone marrow transplants may be effective in treating systemic mastocytosis, a rare blood disease with no known cure, and the use of vaccines to replace antivirals which can often spawn deadly infections. Dr

Read more about Ryotaro Nakamura, MD

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

Read more about Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

Mutations in the tumor suppressor gene TP53 are detected in 5-10% of patients with acute myeloid leukemia acute myeloid leukemia: (

Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes

Read more about Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

Read more about High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

We examined the association between serum ferritin ferritin: (FER-i-tin) A protein inside of cells that stores iron for later use by your body. Sometimes ferritin is released into the blood.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Read more about A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes myelodysplast

Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

Read more about Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

Background: The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients' health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients' HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible.

Guideline-based indicators for adult patients with myelodysplastic syndromes

Read more about Guideline-based indicators for adult patients with myelodysplastic syndromes

Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone

Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes

Read more about Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes

Background: The development of novel therapies for the myelodysplastic syndromes myelodysplastic syndromes:

Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges

Read more about Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges

The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the

Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium

Read more about Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium

Background: Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A

Subscribe to Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

Ryotaro Nakamura, MD

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience

Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

Guideline-based indicators for adult patients with myelodysplastic syndromes

Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes

Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges

Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium

Website Feedback

Patient Helpline